John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$257M |
| 2 |
Boston Scientific
BSX
|
+$228M |
| 3 |
Meta Platforms (Facebook)
META
|
+$225M |
| 4 |
Amazon
AMZN
|
+$220M |
| 5 |
S&P Global
SPGI
|
+$219M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$252M |
| 2 |
PayPal
PYPL
|
+$252M |
| 3 |
Walt Disney
DIS
|
+$217M |
| 4 |
Chevron
CVX
|
+$206M |
| 5 |
Best Buy
BBY
|
+$152M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.83% |
| 2 | Consumer Discretionary | 13.53% |
| 3 | Financials | 9.1% |
| 4 | Healthcare | 9.07% |
| 5 | Consumer Staples | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
2026
PUT
S&P Global
SPGI
$128B
| $986K | ﹤0.01% |
3,000
-400
| -12% | -$135K |
|
|
SVC
2027
Service Properties Trust
SVC
$1.03B
| $983K | ﹤0.01% |
+17,112
| New | +$870K |
|
2028
PUT
Trupanion
TRUP
$1.4B
| $982K | ﹤0.01% |
8,200
+4,200
| +105% | +$397K |
|
|
AXON
2029
CALL
Axon Enterprise
AXON
$49.8B
| $980K | ﹤0.01% |
8,000
-32,000
| -80% | -$3.67M |
|
|
HBI
2030
CALL
DELISTED
Hanesbrands
HBI
| $980K | ﹤0.01% |
67,200
+28,900
| +75% | +$436K |
|
|
SLNO
2031
DELISTED
Soleno Therapeutics
SLNO
| $980K | ﹤0.01% |
33,841
-5,666
| -14% | -$164K |
|
2032
Cooper-Standard Automotive
CPS
$474M
| $978K | ﹤0.01% |
+28,199
| New | +$785K |
|
2033
PUT
Diamondback Energy
FANG
$56B
| $978K | ﹤0.01% |
20,200
-92,700
| -82% | -$3.43M |
|
2034
PUT
Nutrien
NTR
$34.8B
| $978K | ﹤0.01% |
+20,300
| New | +$897K |
|
|
VRTV
2035
DELISTED
VERITIV CORPORATION
VRTV
| $976K | ﹤0.01% |
46,949
+27,620
| +143% | +$496K |
|
|
CYBR
2036
CALL
DELISTED
CyberArk
CYBR
| $970K | ﹤0.01% |
+6,000
| New | +$698K |
|
2037
PUT
HCA Healthcare
HCA
$92.8B
| $970K | ﹤0.01% |
+5,900
| New | +$863K |
|
|
ARAV
2038
DELISTED
Aravive, Inc. Common Stock
ARAV
| $969K | ﹤0.01% |
171,720
+31,282
| +22% | +$172K |
|
2039
Lindsay Corp
LNN
$1.16B
| $968K | ﹤0.01% |
+7,538
| New | +$860K |
|
2040
State Street SPDR S&P Retail ETF
XRT
$325M
| $966K | ﹤0.01% |
15,012
+4,300
| +40% | +$247K |
|
2041
Lineage Cell Therapeutics
LCTX
$286M
| $963K | ﹤0.01% |
547,215
+337,210
| +161% | +$472K |
|
2042
PUT
Fastenal
FAST
$57.7B
| $962K | ﹤0.01% |
39,400
+21,600
| +121% | +$508K |
|
2043
PUT
Invesco
IVZ
$14.4B
| $962K | ﹤0.01% |
55,200
+35,300
| +177% | +$543K |
|
2044
PUT
Cencora
COR
$62.6B
| $958K | ﹤0.01% |
9,800
+2,300
| +31% | +$230K |
|
2045
CALL
Workday
WDAY
$48B
| $958K | ﹤0.01% |
4,000
+2,000
| +100% | +$449K |
|
|
2046
PUT
Workday
WDAY
$48B
| $958K | ﹤0.01% |
4,000
-1,000
| -20% | -$225K |
|
2047
CALL
Honeywell
HON
$68.4B
| $957K | ﹤0.01% |
+4,775
| New | +$867K |
|
2048
VEON
VEON
$4.29B
| $957K | ﹤0.01% |
+25,358
| New | +$903K |
|
2049
Forestar Group
FOR
$1.48B
| $956K | ﹤0.01% |
47,391
+27,033
| +133% | +$514K |
|
2050
CALL
Oneok
OKE
$57.8B
| $956K | ﹤0.01% |
24,900
-64,200
| -72% | -$2.16M |
|
Similar funds
John Overdeck's Q4 2020 Portfolio in Review
As of Q4 2020, John Overdeck held 3,971 positions worth $34.9B, up 24% from $28.2B the previous quarter. Its ten largest holdings account for 7.4% of the portfolio.
John Overdeck deployed $1.95B of net new capital in Q4 2020, opening 955 new positions and adding to 1,167 existing holdings. Its largest new stake was Boston Scientific: 6,312,819 shares worth $227M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Chevron, an estimated $206M trimmed.
- John Overdeck's largest Q4 2020 buy was Boston Scientific: 6,312,819 shares worth $227M.
- John Overdeck added most to NVIDIA in Q4 2020, an estimated $257M increase.
- John Overdeck's biggest Q4 2020 reduction was Chevron, cutting an estimated $206M.
- John Overdeck fully exited Pfizer in Q4 2020, selling an estimated $252M.
- John Overdeck's ten largest holdings make up 7.4% of its $34.9B portfolio in Q4 2020.
- John Overdeck opened 955 new positions and closed 694 in Q4 2020.
- John Overdeck's portfolio value rose 24% quarter-over-quarter to $34.9B.
Based on Two Sigma Investments's 13F filing for Q4 2020, filed 16 Feb 2021.